Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR -Activating Mutations | SpringerLink
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. | Semantic Scholar
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR -Activating Mutations | SpringerLink
OncoPrescribe - Write The Perfect Prescription
References in Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial - The Lancet Oncology
Critical Review of <i>EGFR</i>-Mutated NSCLC: What We Do and Do Not Know - Open Access | healthbook
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review)
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.,Cancer Science - X-MOL
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations - ScienceDirect
Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations | Business Wire
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial - Journal of Thoracic Oncology
Vizimpro 45 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials - ScienceDirect
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck† - Annals of Oncology
Innovación en terapia sistémica de cáncer de pulmón
PDF) Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Table 2 from Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. | Semantic Scholar
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial - The Lancet Oncology
P76.67 Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050 - Journal of Thoracic Oncology
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-sm | OTT
Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors - Vera Hirsh, 2018
PP-DAC-USA-0041 VIZIMPRO® (dacomitinib) Fact Sheet ABOUT VIZIMPRO VIZIMPRO® (dacomitinib) is a kinase inhibitor for the first-
Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application | Future Oncology
